226 related articles for article (PubMed ID: 31557599)
1. ATR kinase inhibition sensitizes quiescent human cells to the lethal effects of cisplatin but increases mutagenesis.
Hutcherson RJ; Kemp MG
Mutat Res; 2019 Nov; 816-818():111678. PubMed ID: 31557599
[TBL] [Abstract][Full Text] [Related]
2. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
3. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
5. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
6. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
[TBL] [Abstract][Full Text] [Related]
7. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM
Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP
Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806
[TBL] [Abstract][Full Text] [Related]
9. ATR Kinase Inhibition Protects Non-cycling Cells from the Lethal Effects of DNA Damage and Transcription Stress.
Kemp MG; Sancar A
J Biol Chem; 2016 Apr; 291(17):9330-42. PubMed ID: 26940878
[TBL] [Abstract][Full Text] [Related]
10. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
11. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
12. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.
Wang C; Wang G; Feng X; Shepherd P; Zhang J; Tang M; Chen Z; Srivastava M; McLaughlin ME; Navone NM; Hart GT; Chen J
Oncogene; 2019 Apr; 38(14):2451-2463. PubMed ID: 30532030
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
15. Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitors.
Schleicher EM; Dhoonmoon A; Jackson LM; Clements KE; Stump CL; Nicolae CM; Moldovan GL
PLoS Genet; 2020 Nov; 16(11):e1009176. PubMed ID: 33137164
[TBL] [Abstract][Full Text] [Related]
16. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
[TBL] [Abstract][Full Text] [Related]
18. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
19. ATR Kinase Activity Limits Mutagenesis and Promotes the Clonogenic Survival of Quiescent Human Keratinocytes Exposed to UVB Radiation.
Shaj K; Hutcherson RJ; Kemp MG
Photochem Photobiol; 2020 Jan; 96(1):105-112. PubMed ID: 31554014
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60).
Vávrová J; Zárybnická L; Lukášová E; Řezáčová M; Novotná E; Sinkorová Z; Tichý A; Pejchal J; Durišová K
Radiat Environ Biophys; 2013 Nov; 52(4):471-9. PubMed ID: 23934411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
